Profile data is unavailable for this security.
About the company
Fagron NV, formerly Arseus NV, is a Belgium-based company that is active in the healthcare sector. The Company specializes in the development, marketing and distribution of healthcare products and services intended for healthcare professionals and institutions. It operates through the following segments: Essentials, enable pharmacists to compound safe products and optimize their compounding process with equipment and packaging. The portfolio includes pharmaceutical raw materials, compounding equipment, packaging, and supplies; Brands, focuses on developing semi-finished products and pharmaceutical-grade vehicles and reduce the workload for pharmacists; Compounding Services, utilizes raw materials from the Essentials segment and vehicles from the Brands segment for compounding activities, offering both sterile and non-sterile compounded products tailored to patients' specific needs.
- Revenue in EUR (TTM)762.99m
- Net income in EUR70.55m
- Incorporated2007
- Employees3.46k
- LocationFagron NVVenecoweg 20ANAZARETH 9810BelgiumBEL
- Phone+32 80012880
- Fax+32 92162491
- Websitehttps://fagron.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abivax SA | 0.00 | -147.74m | 891.07m | 40.00 | -- | 4.55 | -- | -- | -3.35 | -3.35 | 0.00 | 3.12 | 0.00 | -- | -- | 0.00 | -73.79 | -65.49 | -96.88 | -94.75 | -- | -- | -- | -- | -- | -8.05 | 0.2206 | -- | -- | -- | -111.52 | -- | -19.06 | -- |
| Polypeptide Group AG | 324.74m | -51.42m | 984.16m | 1.20k | -- | 2.57 | -- | 3.03 | -1.51 | -1.51 | 9.53 | 11.24 | 0.5137 | 2.31 | 5.08 | 262,612.20 | -8.13 | 2.59 | -10.37 | 3.26 | 2.81 | 23.73 | -15.83 | 4.58 | 1.12 | -1.56 | 0.2466 | 15.79 | 14.60 | 12.36 | -762.29 | -- | 25.40 | -- |
| AddLife AB | 829.51m | 16.36m | 988.05m | 2.30k | 62.46 | 2.41 | 10.29 | 1.19 | 1.57 | 1.57 | 79.48 | 40.69 | 0.7507 | 3.69 | 6.94 | 4,209,040.00 | 1.49 | 5.31 | 2.25 | 8.83 | 37.16 | 36.88 | 1.98 | 5.79 | 0.4541 | 1.66 | 0.5085 | 31.73 | 6.62 | 31.30 | -60.42 | 8.00 | 44.43 | -1.89 |
| FAES Farma SA | 451.17m | 91.90m | 994.52m | 1.75k | 10.63 | 1.48 | 8.95 | 2.20 | 0.2959 | 0.2959 | 1.45 | 2.13 | 0.6009 | 1.26 | 3.96 | 258,105.30 | 12.21 | 13.07 | 13.91 | 15.20 | 65.86 | 64.10 | 20.32 | 19.79 | 1.86 | -- | 0.0348 | -- | 2.83 | 6.83 | 2.63 | 12.24 | 39.26 | -- |
| BioGaia AB | 111.04m | 31.29m | 999.82m | 210.00 | 33.17 | 5.97 | 29.88 | 9.00 | 3.62 | 3.62 | 12.84 | 20.11 | 0.5703 | 2.14 | 10.96 | 6,173,838.00 | 16.07 | 15.47 | 17.45 | 16.93 | 73.29 | 73.30 | 28.18 | 27.70 | 8.65 | -- | 0.0043 | 104.42 | 17.44 | 11.81 | -2.25 | 11.20 | 29.27 | 28.10 |
| EIS czcbs lc Sn v Fnnsl Ytrmlr Sny v Tcr | 126.02m | 108.04m | 1.02bn | 1.12k | 9.40 | 1.89 | 8.70 | 8.06 | 5.45 | 5.45 | 6.36 | 27.09 | 0.2564 | 3.43 | 7.13 | 3,764,577.00 | 21.98 | 15.36 | 24.37 | 16.30 | 43.46 | 34.58 | 85.74 | 113.93 | 1.24 | -- | 0.1317 | -- | 65.89 | 25.08 | 230.63 | 97.42 | 82.99 | -- |
| Vetoquinol SA | 525.26m | 58.83m | 1.16bn | 2.52k | 19.67 | 2.29 | 12.91 | 2.21 | 4.97 | 4.97 | 44.40 | 42.73 | 0.8243 | 2.14 | 5.35 | 208,353.00 | 9.23 | 6.95 | 11.54 | 9.21 | 50.66 | 61.26 | 11.20 | 8.63 | 1.70 | -- | 0.0303 | 16.18 | 3.55 | 8.92 | -23.65 | 6.62 | 10.42 | 11.70 |
| BioArctic AB | 52.76m | 19.63m | 1.24bn | 83.00 | 76.42 | 16.62 | 58.59 | 23.56 | 2.58 | 2.58 | 6.97 | 11.85 | 0.6026 | -- | -- | -- | 22.43 | 2.24 | 24.80 | 2.56 | 91.73 | 86.52 | 37.22 | 9.76 | -- | -- | 0.0047 | 0.00 | 169.83 | -2.91 | 2,150.71 | -9.69 | -- | -- |
| Cosmo Pharmaceuticals NV | 96.69m | 1.15m | 1.28bn | 325.00 | 1,021.55 | 2.74 | 81.77 | 13.20 | 0.0692 | 0.0692 | 5.83 | 25.83 | 0.1473 | 3.06 | 2.88 | 289,187.10 | 0.2051 | 0.2437 | 0.249 | 0.267 | 59.33 | 57.28 | 1.39 | 2.10 | 3.80 | 2.73 | 0.0042 | 841.86 | -5.26 | 8.07 | -93.34 | -- | 9.62 | -- |
| Fagron NV | 762.99m | 70.55m | 1.31bn | 3.46k | 18.52 | 2.82 | 12.14 | 1.72 | 0.9664 | 0.9664 | 10.45 | 6.35 | 0.7715 | 3.87 | 12.43 | 220,517.60 | 7.18 | 7.63 | 8.76 | 9.77 | 43.59 | 43.49 | 9.31 | 10.23 | 1.27 | 4.45 | 0.4395 | 16.28 | 11.57 | 10.10 | 1.34 | 10.48 | 19.64 | 20.11 |
| Bonesupport Holding AB | 50.62m | 20.99m | 1.34bn | 110.00 | 64.01 | 28.92 | 62.01 | 26.49 | 3.72 | 3.72 | 9.04 | 8.24 | 1.11 | 0.7186 | 6.60 | 5,373,428.00 | 46.20 | -9.08 | 58.31 | -11.28 | 91.51 | 90.25 | 41.45 | -11.65 | 2.46 | -- | 0.0311 | -- | 79.76 | 43.65 | 459.44 | -- | 18.39 | -- |
| Genus plc | 785.04m | 38.95m | 1.35bn | 3.48k | 34.67 | 2.01 | 15.00 | 1.72 | 0.5053 | 0.5053 | 10.18 | 8.71 | 0.6478 | -- | 6.03 | 193,642.10 | 2.90 | 3.58 | 3.30 | 4.20 | -- | -- | 4.47 | 5.44 | 1.40 | 5.44 | 0.3377 | 60.86 | 16.23 | 7.96 | -18.58 | 26.70 | 9.36 | 4.24 |
| Biotest AG | 684.60m | 127.00m | 1.39bn | 2.43k | 12.96 | 3.30 | -- | 2.04 | 3.21 | 3.21 | 17.30 | 12.61 | 0.5238 | 1.13 | 3.84 | 282,192.90 | 9.72 | -0.0693 | 12.10 | -0.079 | 40.94 | 28.43 | 18.55 | -0.1527 | 0.8757 | 3.86 | 0.5803 | -- | 32.65 | 11.33 | 490.89 | -- | -9.36 | -- |
| Bavarian Nordic A/S | 946.53m | 197.71m | 1.56bn | 1.38k | 7.66 | 1.12 | 5.74 | 1.65 | 19.46 | 19.46 | 92.83 | 132.47 | 0.5281 | 1.92 | 6.10 | 5,121,349.00 | 11.03 | 1.21 | 13.62 | 1.48 | 65.18 | 53.72 | 20.89 | 4.06 | 1.35 | -- | 0.0139 | 0.00 | 124.14 | 69.78 | 524.66 | -- | 35.76 | -- |
| Almirall SA | 894.52m | -38.47m | 1.70bn | 1.90k | -- | 1.16 | -- | 1.90 | -0.1757 | -0.1757 | 4.27 | 6.99 | 0.3956 | 1.43 | 8.23 | 469,808.80 | -1.70 | 0.922 | -1.97 | 1.08 | 76.25 | 78.06 | -4.30 | 2.48 | 1.57 | 8.54 | 0.216 | -- | 3.62 | 3.40 | -998.72 | -- | -23.27 | -- |
| Dermapharm Holding SE | 1.14bn | 62.37m | 1.72bn | 3.50k | 27.55 | 3.19 | 10.41 | 1.52 | 1.16 | 1.16 | 21.09 | 10.01 | 0.6354 | 1.44 | 12.10 | 324,664.30 | 3.39 | 8.68 | 4.10 | 10.06 | 63.34 | 61.94 | 5.33 | 12.31 | 0.7852 | 2.56 | 0.6647 | 54.69 | 10.79 | 14.68 | -53.54 | -3.70 | 9.85 | -- |
Data as of Apr 18 2024. Currency figures normalised to Fagron NV's reporting currency: Euro EUR
46.59%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Goldman Sachs Asset Management BVas of 31 Dec 2022 | 11.61m | 15.85% |
| Active Ownership Corp SARLas of 19 Dec 2023 | 8.10m | 11.07% |
| Mawer Investment Management Ltd.as of 31 Dec 2022 | 2.20m | 3.01% |
| Kabouter Management LLCas of 26 Aug 2022 | 2.14m | 2.92% |
| Templeton Investment Counsel LLCas of 13 Sep 2022 | 2.14m | 2.92% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 2.04m | 2.79% |
| Fidelity Management & Research Co. LLCas of 29 Feb 2024 | 1.81m | 2.48% |
| JPMorgan Asset Management (UK) Ltd.as of 29 Feb 2024 | 1.78m | 2.43% |
| BNP Paribas Asset Management Belgium SAas of 29 Feb 2024 | 1.18m | 1.62% |
| Tweedy, Browne Co. LLCas of 29 Dec 2023 | 1.12m | 1.53% |
More ▼
Data from 19 Dec 2023 - 11 Apr 2024Source: FactSet Research Systems Inc.
